Lasa Supergenerics Ltd vs Remus Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Lasa Supergenerics Ltd is ₹ 7.87 as of 05 May 15:30 . The P/E Ratio of Lasa Supergenerics Ltd is 0 as of March 2024 .The P/E Ratio of Remus Pharmaceuticals Ltd is 49.4 as of March 2024 . The Market Cap of Lasa Supergenerics Ltd is ₹ 0 crore as of March 2024 .The Market Cap of Remus Pharmaceuticals Ltd is ₹ 1016 crore as of March 2024 . The revenue of Lasa Supergenerics Ltd for the Dec '25 is ₹ 2.22 crore as compare to the Sep '25 revenue of ₹ 3.07 crore. This represent the decline of -27.69% The revenue of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Lasa Supergenerics Ltd for the Dec '25 is ₹ -0.73 crore as compare to the Sep '25 ebitda of ₹ -3.99 crore. This represent the decline of -81.7% The ebitda of Remus Pharmaceuticals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Lasa Supergenerics Ltd changed from ₹ -2.73 crore to ₹ -2.55 crore over 7 quarters. This represents a CAGR of -3.82% The net profit of Remus Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Lasa Supergenerics Ltd changed from 4.46 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Remus Pharmaceuticals Ltd changed from 2.56 % on March 2023 to 4.44 % on March 2025 . This represents a CAGR of 20.15% over 3 years .

About Lasa Supergenerics Ltd

Lasa Supergenerics Limited was incorporated on March 11, 2016.
The Company is primarily engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, Pharmaceuticals, drugs, etc. The Company is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain-from discovery-to-delivery, with established credentials in research, manufacturing and global marketing.
The Company is a veterinary API manufacturing entity, which was acquired in April, 2012.
The manufacturing facility is located at Mahad & Chiplun, in the Konkan region of Maharashtra.
It specialises in catalyst chemistry' and manufactures anthelmintic / veterinary API products with largest production capabilities and product categories in India.

About Remus Pharmaceuticals Ltd

Remus Pharmaceuticals Limited was originally incorporated as Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat.
Subsequently, Company converted from a Private to Public and the name of the Company was changed to 'Remus Pharmaceuticals Limited' on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs.
It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries.
The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.

FAQs for the comparison of Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd

Which company has a larger market capitalization, Lasa Supergenerics Ltd or Remus Pharmaceuticals Ltd?

Market cap of Lasa Supergenerics Ltd is 40 Cr while Market cap of Remus Pharmaceuticals Ltd is 844 Cr

What are the key factors driving the stock performance of Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd?

The stock performance of Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd?

As of May 5, 2026, the Lasa Supergenerics Ltd stock price is INR ₹8.16. On the other hand, Remus Pharmaceuticals Ltd stock price is INR ₹716.8.

How do dividend payouts of Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd compare?

To compare the dividend payouts of Lasa Supergenerics Ltd and Remus Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.